Insuman Rapid (Insulin Human)

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen storage, and suppress glucose production by the liver. This coordinated action reduces circulating glucose concentrations.

The dose of Insuman Rapid is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood‑glucose readings, carbohydrate intake, and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional.

Insuman Rapid may be used in pregnancy or while breastfeeding only if the potential benefit outweighs any risk. Treatment decisions should be made by a physician familiar with the patient’s condition, as insulin is the preferred glucose‑lowering therapy when needed during these periods.

To order Insuman Rapid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Insuman Rapid contains human insulin, whereas many newer rapid‑acting analogues are modified molecules (e.g., insulin lispro, aspart). Both provide quick onset, but analogues may have slightly different pharmacokinetic profiles and lower risk of post‑prandial hypoglycaemia. Choice depends on clinical response, physician preference and regulatory availability.

Insuman Rapid must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, but should not be shaken.

Insuman Rapid is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. In some clinical situations, intravenous administration may be used under medical supervision. The injection should be given shortly before meals to match the rapid rise in post‑prandial glucose.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to have a rapid source of glucose available.

Insuman Rapid should be avoided in individuals with known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia until glucose levels are corrected, and in those for whom insulin therapy is not indicated.